GCGR and type 2 diabetes mellitus: Cotadutide, a once-daily GLP-1 and glucagon receptor dual agonist, demonstrated optimal weight loss and glycaemic control in a 48-day phase 2a study in Japanese adults with type 2 diabetes [24].